Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 7 of 23

  1. IVPT

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  2. Ibudilast

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  3. Immune Globulin Intravenous (IVIG)

    BRIGHT MINDS BIOSCIENCES INC.

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  4. Immunization with P. vivax irradiated sporozoites

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria

    phase 2 mab completed

    1 trial

  5. Inactive Marijuana (0% THC)

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Smoking

    phase 2 small molecule completed

    1 trial

  6. Interactive injection and sexual risk intervention

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  7. Intermittent Oral Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine

    phase 2 small molecule completed

    1 trial

  8. Intervention Condition

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  9. Isradipine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  10. KLWS-V502-02

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial

  11. Ketamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  12. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  13. L-Glutamine

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Hypertension

    phase 2 small molecule completed

    1 trial

  14. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  15. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 2 other completed

    1 trial

  16. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  17. LX1001

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 mab completed

    1 trial

  18. Labetalol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  19. Lamotrigine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  20. Lemborexant

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interaction

    phase 2 small molecule completed

    1 trial

  21. Lidocaine HCl

    BRIGHT MINDS BIOSCIENCES INC.

    Postherpetic Neuralgia

    phase 2 small molecule active

    1 trial

  22. Linezolid

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  23. Linezolid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Meningeal

    phase 2 small molecule completed

    1 trial

  24. Liraglutide Pen Injector

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Substitution Treatment

    phase 2 small molecule completed

    1 trial

  25. Lisdexamfetamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  26. Lithium Carbonate

    BRIGHT MINDS BIOSCIENCES INC.

    Frontotemporal Dementia (FTD)

    phase 2 small molecule completed

    1 trial

  27. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  28. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule completed

    1 trial

  29. Lorazepam

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule terminated

    1 trial

  30. Lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 2 small molecule completed

    1 trial

  31. Lorcaserin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  32. Low Dose Modafinil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  33. M-CPP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    2 trials

  34. MI-CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Abuse

    phase 2 other completed

    1 trial

  35. MI/CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholic, Marijuana Misuse

    phase 2 other completed

    1 trial

  36. MN-166 (50 mg) First

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Abuse

    phase 2 small molecule completed

    1 trial

  37. Marijuana blunt

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule completed

    1 trial

  38. Matching placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Familial Dysautonomia

    phase 2 small molecule active

    1 trial

  39. Mazindol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  40. Memantine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  41. Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)

    BRIGHT MINDS BIOSCIENCES INC.

    Meningitis

    phase 2 mab active

    1 trial

  42. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  43. Methamphetamine

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Intoxication

    phase 2 small molecule active

    1 trial

  44. Micronized Progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  45. Mindfulness Based Relapse Prevention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  46. Mirtazapine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  47. Mirtazapine

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 2 small molecule completed

    1 trial

  48. Mirtazapine 15 MG Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.